ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
41 announcements
Eris Lifesciences reported audited FY26 results and declared an interim dividend of Rs. 7.21 per share. The company recorded consolidated annual net profit of ₹647.51 Crore.
Eris Lifesciences fixed May 24, 2026, as the record date for NCD interest payments. Payments for two ISINs are scheduled for June 8, 2026.
Eris Lifesciences subsidiary received 'IND AA/Stable/IND A1+' ratings for ₹520 Crore banking facilities. The action reflects strong parent linkages and robust operating performance.
Eris Lifesciences allotted 24,396 equity shares under its ESOP-2021 Scheme. The allotment raised approximately ₹1.48 Crore, increasing the company's total paid-up share capital.
India Ratings affirmed Eris Lifesciences Limited's long-term issuer rating at 'IND AA' with a stable outlook. The affirmation covers ₹2,448.00 Crore in NCDs and bank facilities.
Eris Lifesciences Limited submitted its annual disclosure for the centralized database of corporate bonds/debentures for the financial year ended March 31, 2026. The report details two outstanding NCD series (ISINs: INE406M08011 and INE406M08029) listed on the BSE, confirming timely interest payments and no defaults during the period.
Eris Lifesciences Limited has issued a postal ballot notice seeking shareholder approval via special resolution for the appointment of Mr. Vineet Varma as an Independent Director. The proposed tenure is for five years, effective from March 14, 2026, to March 13, 2031.
Eris Lifesciences Limited has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Vineet Varma as an Independent Director for a five-year term. The remote e-voting period runs from April 24, 2026, to May 23, 2026. This appointment aims to strengthen the board with his extensive international banking experience.
Eris Lifesciences' subsidiary, Swiss Parenterals Ltd, received non-compliance observations from HALMED, Croatia, following inspections of its Ahmedabad units. The company will execute remediation actions to reinstate approvals. While existing business impact is minimal, the observations will delay the commercialization of the EU-CDMO product pipeline.
Eris Lifesciences Limited submitted its half-yearly statement for debt securities ended March 31, 2026. The company has two outstanding NCD issuances totaling ₹1,250 Crore, with coupon rates of 8.73% and maturities in 2026 and 2027. This filing ensures compliance with SEBI reporting norms for listed debt instruments.
Eris Lifesciences Ltd reported net profit of ₹109 Cr (+25.1% YoY) for Q3 FY26.